DXM's Psychedelic Potential: Implications for Research

DXM: From Cough Suppressant to Psychedelic Agent

Dextromethorphan (DXM), a common over-the-counter antitussive, is gaining attention for its potential psychedelic effects at higher doses. A recent systematic review, published on June 15, 2026, explores DXM's psychoactive properties and its possible role in treating psychiatric disorders. The review, conducted under PRISMA guidelines and registered in PROSPERO, highlights the need for further research to establish therapeutic dosing and safety profiles.

Mechanism and Context

DXM is known to exhibit psychoactive effects that overlap with those of classic and dissociative psychedelics. At supratherapeutic levels, it can induce hallucinatory and mystical experiences, similar to substances like ketamine and psilocybin. The review identified eight studies, including randomized controlled trials and observational studies, that reported psychedelic effects at doses as low as 100 mg, with intensified phenomena at 300 to 400 mg.

The potential of DXM as a therapeutic agent for treatment-resistant psychiatric disorders is intriguing but remains underexplored. The systematic review underscores the need for more robust, prospective studies to better understand the dose-response relationships and safety concerns associated with DXM.

Research Implications and Policy Considerations

While the existing evidence is limited, DXM's potential as a therapeutic psychedelic agent could expand the scope of psychedelic research. The review calls for larger, prospectively designed studies to establish clear dose-response relationships and assess clinical applicability. Policymakers and researchers must collaborate to ensure that future studies address these gaps, potentially leading to new therapeutic options for psychiatric disorders.

Risks and Unknowns

Despite its potential, DXM poses significant risks at higher doses. Adverse effects such as nausea, vomiting, motor impairment, and cognitive slowing become more prominent above 200 mg. The review also highlights the low certainty of evidence for most primary outcomes, emphasizing the need for caution in interpreting current findings. The risk of bias in the reviewed studies further complicates the assessment of DXM's psychedelic potential.

Looking Forward

The exploration of DXM's psychedelic properties is in its early stages, with much left to uncover. Future research must prioritize safety and efficacy, focusing on well-designed clinical trials to determine appropriate dosing and therapeutic applications. As the field of psychedelic research continues to evolve, DXM may emerge as a valuable tool in the treatment of psychiatric disorders, provided that its risks are thoroughly understood and managed.